32 results about "Heparan sulphate" patented technology

Heparan sulphate HS7 is disclosed, together with the use of HS7 in the growth and / or development and / or regeneration of tissue.

The invention relates to composition comprising a dextran-tyramine conjugate and a conjugate selected from the group consisting of chondroitin sulphate-tyramine, collagen-tyramine, chitosan-tyramine, chitosan-phloretic acid, gelatine-tyramine, heparan sulphate-tyramine, keratin sulphate-tyramine, hyaluronic acid-tyramine and heparin-tyramine.

The present invention relates to an anti-HIV composition and to the method for producing it. The composition of the present invention comprises a polyanion and a molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein. The polyanion may be chosen, for example, from the group consisting of heparin, heparan sulphate, and a polyanion equivalent to heparin or to heparan sulphate. The molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein is a CD4 peptide or a derivative thereof. The present invention also relates to the use of said composition for producing a medicinal product, in particular a medicinal product intended for the treatment of AIDS.

A novel class of structurally and functionally related isolated Heparan sulphate is disclosed. The novel class of Heparan sulphates has been found to bind FGF2 and enhance the proliferation of stem cells while maintaining their pluripotency / multipotency.

The invention provides an identification method and application of heparin and heparan sulfate, and belongs to the technical field of medicine detection. Research finds that eight disaccharide components of 0S, NS, 6S, 2S, 2SNS, 6SNS, 2S6S and TriS are rich in heparin drugs, and can be well used for identifying heparin and heparan sulfate as a mixed standard substance. Therefore, a set of quantitative detection method based on hydrophilic interaction chromatography-mass spectrometry is established for the eight components, and the method has the advantages of being easy and convenient to operate, short in consumed time, high in selectivity, high in sensitivity, good in specificity, good in repeatability and the like. The method can be used for simply, conveniently and accurately identifying heparin and heparan sulfate, a method and data reference are provided for constructing a more complete quality control standard system of glycosaminoglycan drugs, so that the method has good practical application value.

The use of Herapan Sulphate 2 (HS-2) in therapeutic bone growth and regeneration is described. Herapan Sulphate 2 was identified as a variant of Heparan Sulphate purified from embryonic day (E10) of murine neuroepithelia.

A heparan sulphate that binds vitronectin is disclosed.

Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and / or regeneration of connective tissue and bones, and the treatment of wounds.

The invention discloses a method for separating and purifying sulodexide raw materials from heparin by-products. After dissolving the heparin by-products, high-temperature precipitation is adopted to separate the crude heparan sulfate and dermatan sulfate; then the crude product solution is passed through hydrogen peroxide -Sulodexide is prepared by oxidative precipitation and drying in an ozone system, and the invention relates to the technical field of medicine. In the method for separating and purifying the raw material drug of sulodexide from the by-product of heparin, the hydrogen peroxide-ozone system is adopted in the oxidation, which can improve the oxidation effect and effectively remove the pigment protein and impurities. The high-temperature precipitation method during precipitation increases the titer recovery rate by 10% compared with the traditional low-temperature precipitation method, and also reduces the use of centrifuges and ion exchange resins, saves 60% of the time compared to simple hydrogen peroxide treatment, and improves product quality. and production efficiency, suitable for large-scale industrial production, short cycle, low cost, full and effective utilization of heparin by-products, high product purity and strong stability.

The present invention refers to the use of certain sulfated glycosaminoglycans for treatment or prevention of postpartum haemorrhage. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with at least one uterotonic agent capable of promoting myometrial contractions of the uterus and thereby compress the vessels and cease the bleeding.

The invention discloses a preparation method of ultrahigh-purity heparan sulfate. The preparation method comprises the following steps: dissolving and precipitating a heparin sodium byproduct to obtain a heparan sulfate crude product; and carrying out secondary dissolution, oxidation and cold precipitation on the heparan sulfate crude product to obtain supernatant, precipitating again, re-dissolving, adsorbing, eluting and precipitating to finally obtain the ultra-high purity heparan sulfate. According to the method, the problem that heparan sulfate is difficult to separate from dermatan sulfate, chondroitin sulfate and heparin sodium is solved, the yield and purity of heparan sulfate are improved, and in addition, the method is simple to operate, stable in product quality and suitable forlarge-scale production.

The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical and cosmeceutical compositions containing the compounds, and methods of treating cancer, inflammation, diabetic nephropathy, neurodegenerative disorders, Niemann-Pick Type C disease, or dermatological conditions.

The method discloses a method for extracting high-purity heparan sulfate from heparan production wastes, and aims at providing a method used for extracting purified heparan sulfate taking the heparanproduction wastes as raw material. The method has the advantages of low cost, convenient operation and easy industrial scaling. The method is characterized by comprising the steps that 1), the heparanproduction wastes are prepared into a solution; 2), acid is added to adjust the pH to 1.9-2.3, ethanol is added, and stirring, centrifugation and standing are conducted; 3), supernatant liquid is collected, aqueous alkali is added to adjust pH to 6-8, and water is added; 4), absorbent is added to the solution is step 3), and stirring is conducted until all mucopolysaccharide in the solution is absorbed by the absorbent; 5), the absorbent is collected and washed with clean water, a sodium chloride solution is added to conduct elution, elution liquid is collected after the elution is completed,and precipitant is added for precipitation; 6), precipitations are collected and dried; the method belongs to the field of mucopolysaccharide pharmaceuticals.

Affinity purification of platelet-derived growth factor-binding heparan sulphate from porcine mucosa (HS6) is disclosed. Also disclosed is the use of HS6 in repair and regeneration of the skin for treating wounds, burns, ulcers and other skin injuries.

The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical and cosmeceutical compositions containing the compounds, and methods of treating cancer, inflammation, diabetic nephropathy, neurodegenerative disorders, Niemann-Pick Type C disease, or dermatological conditions.

The present invention relates to an anti-HIV composition and to the method for producing it.The composition of the present invention comprises a polyanion and a molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein. The polyanion may be chosen, for example, from the group consisting of heparin, heparan sulphate, and a polyanion equivalent to heparin or to heparan sulphate. The molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein is a CD4 peptide or a derivative thereof.The present invention also relates to the use of said composition for producing a medicinal product, in particular a medicinal product intended for the treatment of AIDS.

Heparan sulphate from bone marrow stroma is disclosed together with the use of heparan sulphate from bone marrow stroma in the differentiation and / or lineage commitment of stem cells.

Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is the use of HS8 in repair and regeneration of the skin for treating wounds, burns, ulcers and other skin injuries.

The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical and cosmeceutical compositions containing the compounds, and methods of treating cancer, inflammation, diabetic nephropathy, neurodegenerative disorders, Niemann-Pick Type C disease, or dermatological conditions.

The present invention relates to a separation method of heparan sulfate and dermatan sulfate in heparin, which comprises the following steps: (a) dissolving heparin in water to prepare heparin solution; (b) passing the heparin solution through anion resin Adsorption; (c) Gradient elution using 0~1mol / L sodium chloride solution, and collecting the eluent of each component; (d) Concentrating the eluent of each component respectively, adding ethanol for precipitation to obtain sulfuric acid Heparan and dermatan sulfate. In this way, heparin-like by-products produced in the production of crude heparin to high-quality heparin can be used as raw materials, which avoids the loss of active ingredients in the prior art, does not introduce impurities, has simple process, low separation cost, good effect, and is easy to scale up.

The present invention refers to the use of certain sulfated glycosaminoglycans for treatment or prevention of postpartum haemorrhage. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with at least one uterotonic agent capable of promoting myometrial contractions of the uterus and thereby compress the vessels and cease the bleeding.

The isolation and identification of glycosaminoglycans capable of binding to proteins having a heparin-binding domain is disclosed, as well as the use of the glycosaminoglycans isolated in the growth and / or development of tissue.